Aptorum Group Limited (APM) - Final Profit

Official company branding of Aptorum Group Limited (APM)

Aptorum Group Limited (APM) is seeing its generated profits soar amid an influx of liquidity, with the metric holding around -0.00. Aptorum Group Limited (APM) attracts biochemists through its interdisciplinary approach and stability. The organization brings together experts for the therapy of orphan pathologies, granting scientists broad autonomy. The business is currently fighting for the attention of major buyers while developing its drug portfolio under constrained resources.

Net Income: aptorumgroup.com (APM) for 07/04/2022 - 07/20/2026

Financial and market metric breakdowns for aptorumgroup.com (APM)

- market value and analyst target forecast:
Stock Price Aptorum Group|APM - Consensus Target
- market capitalization indicators:
Market Value APM|APM - Total Company Value
- business book valuation details:
Net Asset Value per Share Aptorum Group|APM - Company Net Assets|Market Cap to Book Value Multiple aptorumgroup.com|APM - Company Total Assets
- debt and liquidity details:
All Debt to Shareholders' Equity Ratio Aptorum Group Limited|APM - Long-Term Debt to Capital|Current Liabilities to Capital Aptorum Group|APM - Company Debts|Debt to Net Assets Ratio APM|APM - Company Long-Term Debts|Company Short-Term Debts Aptorum Group|Critical Liquidity Ratio aptorumgroup.com
- company profitability and valuation multiples indicators:
APM - Net Income
Basic company analysis:Aptorum (APM)
Manufactured products of Aptorum Group Limited

To minimize risks amid uncertainty, it is crucial for investors to track a business's actual ability to generate cash flow, excluding accounting adjustments. Analyzing the net income trends of Aptorum Group Limited (APM) can reveal the depletion of reserves, which is critical for Aptorum Group Limited (APM) during its R&D portfolio restructuring and search for strategic partners while clinical releases are temporarily deferred.

Direct competitors

Haleon Corp (HLN) - Net Profit|Net Income KVUE|VRNA: Final Profit|Company Net Income Jyong Biotech (MENS)|LGND - Company Net Income|Amneal Pharmaceuticals Inc - Net Income|Profit After Payment of Taxes PRGO (Perrigo Corp)|Alvotech - Net Profit|Final Profit LQDA (liquidia.com)|GLPG: Net Profit|Company Net Income ANI Pharmaceuticals Inc (ANIP)|Company Net Income MannKind Corp.|AMPH: Final Profit|Net Profit PCRX|Net Profit ars-pharma.com (SPRY)|Company Net Income Theravance Biopharma, Inc. TBPH|AQST (Aquestive Therapeutics Inc) - Profit After Tax|SCPH: Net Income|Tectonic Therapeutic, Inc. - Profit After Payment of Taxes|Tonix Pharmaceuticals (TNXP) - Company Net Income|Company Net Income China SXT Pharmaceuticals, Inc. (SXTC)|Company Net Income Eupraxia Pharmaceuticals, Inc.|BHST: Final Profit|Net Income EXOZ (Invizyne Technologies, Inc.)|Net Profit oramed.com (ORMP)|Company Net Income Entera Bio ENTX|HYFT - Net Income|ABVC: Net Income|Final Profit CPIX (Cumberland Pharmaceuticals Inc)|QNTM: Net Profit|Annual Net Income FibroGen Corporation FGEN|Company Net Income Telomir Pharmaceuticals|RANI: Final Profit|Company Net Income Synergy CHC Corp (SNYR)|RLYB - Company Net Income|Lexaria Bioscience Corp. - Net Income|Net Profit Pulmatrix Corporation PULM|PTHL - Company Net Income|Profit After Tax LYRA|IBO (Impact BioMedical Inc) - Net Income|TNF Pharmaceuticals, Inc. - Final Profit|Company Net Income cbdMD Inc.|Company Net Income PRFX|Net Profit CYTO|Net Financial Result lipella.com|Company Net Income OptiNose OPTN|PIRS - Net Income|Procaps Group SA - Net Profit|Net Financial Result Petros Pharma PTPI|QLI (Qilian International) - Net Income|SLRN: Profit After Payment of Taxes|TFFP (TFF Pharmaceuticals, Inc.) - Net Profit